Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

NCT01288417 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT01288417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01288417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
Lead sponsor
Radboud University Medical Center
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2011
Completion date
December 31, 2011
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcv infections, hiv infections